Lupin Launches Generic Glumetza HCI ER Tablets In The US

MUMBAI and BALTIMORE, February 2, 2016 /PRNewswire/ --

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc., has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.'s Glumetza® HCl ER Tablets, 500 mg and 1000 mg.

(Logo: http://photos.prnewswire.com/prnh/20150903/762560-c )

Lupin's Metformin HCl ER Tablets, 500 mg and 1000 mg are the AB-rated generic equivalent of Santarus Inc.'s Glumetza® HCl ER Tablets, 500 mg and 1000 mg strengths. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus.

Lupin is eligible for 180 days of generic drug exclusivity for its Metformin HCl ER Tablets, 500 mg and 1000 mg. Glumetza® HCI ER Tablets had US sales of USD 450.4 million (IMS MAT September 2015).

About Lupin Pharmaceuticals Inc. (LPI):

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.

Please visit http://www.lupin.com for more information. You could also follow us on Twitter - www.twitter.com/lupinlimited.

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.

For further information or queries please contact:
Shamsher Gorawara
Head - Corporate Communications
Ph: +91-9820338555
Email: shamshergorawara@lupin.com

*Safe Harbor Statement
Glumetza® is the registered trademark of Valeant International.

Back to news